Search Results for "Miralax"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Miralax. Results 1 to 10 of 12 total matches.

Comparison Chart: Some Drugs for Irritable Bowel Syndrome with Constipation (IBS-C) (online only)

   
The Medical Letter on Drugs and Therapeutics • Feb 03, 2025  (Issue 1721)
increased slowly to improve tolerability Osmotic Laxative Polyethylene glycol – Miralax (Bayer) 17 g ...
View the Comparison Chart: Some Drugs for Irritable Bowel Syndrome with Constipation (IBS-C)
Med Lett Drugs Ther. 2025 Feb 3;67(1721):e1-3   doi:10.58347/tml.2025.1721e |  Show IntroductionHide Introduction

Plenvu - A Low-Volume PEG-Based Colonoscopy Preparation

   
The Medical Letter on Drugs and Therapeutics • Jan 28, 2019  (Issue 1564)
) and in 93% of those who took a 2-L PEG 3350 (Miralax) and sports drink solution with the stimulant ...
The FDA has approved Plenvu (Salix), a polyethylene glycol (PEG)-containing oral powder for reconstitution, for colon cleansing prior to colonoscopy in adults. Plenvu is the first PEG-containing colonoscopy preparation that requires only 1 L of water for dissolution and ingestion of 1 L of clear fluid in addition.
Med Lett Drugs Ther. 2019 Jan 28;61(1564):11-4 |  Show IntroductionHide Introduction

Figure 1: Treatments for Irritable Bowel Syndrome (IBS) in Adults (online only)

   
The Medical Letter on Drugs and Therapeutics • Feb 03, 2025  (Issue 1721)
linaclotide lubiprostone Miralax polyethylene glycol amitriptyline nortriptyline Ibsrela cholestyramine ...
View Figure: Treatments for Irritable Bowel Syndrome (IBS) in Adults
Med Lett Drugs Ther. 2025 Feb 3;67(1721):e1   doi:10.58347/tml.2025.1721c |  Show IntroductionHide Introduction

Comparison Chart: Safety of Drugs for IBS in Pregnancy and Lactation (online only)

   
The Medical Letter on Drugs and Therapeutics • Feb 03, 2025  (Issue 1721)
given high doses ▶ Not detected in breast milk Polyethylene glycol (Miralax) ▶ Systemic absorption ...
View the Comparison Chart: Safety of Drugs for IBS in Pregnancy and Lactation
Med Lett Drugs Ther. 2025 Feb 3;67(1721):e1-2   doi:10.58347/tml.2025.1721b |  Show IntroductionHide Introduction

Clenpiq - A Low-Volume Sodium Picosulfate-Based Colonoscopy Preparation

   
The Medical Letter on Drugs and Therapeutics • May 21, 2018  (Issue 1547)
as the 4-L preparations and better tolerated. PEG 3350 laxative powder (MiraLAX, and others; available ...
The FDA has approved Clenpiq (Ferring), a low-volume oral solution that contains sodium picosulfate, magnesium oxide, and anhydrous citric acid, for colon cleansing prior to colonoscopy in adults. The ready-to-drink solution contains the same ingredients as Prepopik, which is supplied as a powder for reconstitution.
Med Lett Drugs Ther. 2018 May 21;60(1547):84-6 |  Show IntroductionHide Introduction

Suflave — A Low-Volume Colonoscopy Preparation

   
The Medical Letter on Drugs and Therapeutics • Sep 18, 2023  (Issue 1685)
consisting of PEG 3350 powder (MiraLAX, and others) dissolved in a total of about 2 liters of a sports ...
The FDA has approved Suflave (Sebela/Braintree), a low-volume polyethylene glycol (PEG)- and sulfate-based product for cleansing of the colon prior to colonoscopy in adults. Other oral colonoscopy preparations available in the US are listed in Table 2. Suflave is marketed as tasting better than other products.
Med Lett Drugs Ther. 2023 Sep 18;65(1685):148-51   doi:10.58347/tml.2023.1685b |  Show IntroductionHide Introduction

Colonoscopy Preparations

   
The Medical Letter on Drugs and Therapeutics • Jan 21, 2013  (Issue 1408)
laxative powder (MiraLAX, and generics; available OTC) to 2L of Gatorade. The powder dissolves ...
Colonoscopy remains the preferred method of colorectal cancer screening. Many patients consider cleansing the bowel in preparation for colonoscopy the most unpleasant part of the procedure, but inadequate bowel preparation significantly lowers the diagnostic yield.
Med Lett Drugs Ther. 2013 Jan 21;55(1408):6-7 |  Show IntroductionHide Introduction

Rifaximin (Xifaxan) for Irritable Bowel Syndrome with Diarrhea

   
The Medical Letter on Drugs and Therapeutics • Aug 03, 2015  (Issue 1474)
such as polyethylene glycol (Miralax, and others) can increase the frequency of bowel movements in patients with IBS ...
Rifaximin (Xifaxan – Salix), a minimally absorbed oral antibiotic approved previously to treat travelers' diarrhea and to reduce the risk of recurrent hepatic encephalopathy, has now been approved by the FDA for treatment of irritable bowel syndrome with diarrhea (IBS-D). Eluxadoline (Viberzi – Actavis), a mu-opioid receptor agonist, was also recently approved for IBS-D and will be reviewed in a future issue.
Med Lett Drugs Ther. 2015 Aug 3;57(1474):109-11 |  Show IntroductionHide Introduction

Sodium Sulfate-Based Tablets (Sutab) for Colonoscopy Preparation

   
The Medical Letter on Drugs and Therapeutics • Mar 08, 2021  (Issue 1619)
, then 16 oz clear liquid over next 30 min; repeat about 12 hrs after dose 1 2 L 123.60 MiraLAX (Bayer ...
The FDA has approved an oral tablet formulation of sodium sulfate, magnesium sulfate, and potassium chloride (Sutab – Braintree) for colon cleansing prior to colonoscopy in adults. A sodium sulfate-based oral solution (Suprep) has been available in the US since 2010. Sutab is the second tablet formulation to be approved for bowel cleansing prior to colonoscopy; a sodium phosphate-based tablet (OsmoPrep) was approved earlier.
Med Lett Drugs Ther. 2021 Mar 8;63(1619):33-6 |  Show IntroductionHide Introduction

Vibrant – An Oral Vibrating Capsule for Chronic Idiopathic Constipation

   
The Medical Letter on Drugs and Therapeutics • May 01, 2023  (Issue 1675)
, and over-the-counter (OTC) laxatives such as polyethylene glycol (Miralax, and others) or bisacodyl ...
The Vibrant orally administered vibrating capsule (Vibrant Gastro), an FDA-cleared medical device, is now available by prescription for treatment of adults with chronic idiopathic constipation (CIC) who have not experienced relief of their bowel symptoms by using laxative therapies at the recommended dosage for at least one month. It is the first drug-free treatment to be authorized by the FDA for this indication.
Med Lett Drugs Ther. 2023 May 1;65(1675):65-7   doi:10.58347/tml.2023.1675a |  Show IntroductionHide Introduction